OR WAIT null SECS
Caribou and JAX entered into a license agreement for Caribou’s CRISPR-Cas9 gene editing technology.
On Oct. 25, 2016 Caribou Biosciences and the Jackson Laboratory (JAX) entered into a license agreement to give JAX non-exclusive worldwide rights to Caribou’s CRISPR-Cas9 intellectual property. JAX will use the technology to create genetically engineered mice for research, Caribou said in a press announcement.
Caribou's CRISPR-Cas9 technology targets and cuts DNA to produce precise and controllable changes to the genome. JAX’s will use the gene editing technology to create mouse models that better recapitulate human diseases, enabling researchers to find treatments more quickly. The license from Caribou includes CRISPR-Cas9 technology and intellectual property owned by Caribou as well as foundational CRISPR-Cas9 intellectual property exclusively licensed to Caribou by the Regents of the University of California and the University of Vienna.
"JAX is excited to reach this CRISPR-Cas9 IP agreement with Caribou," said Edison Liu, MD, president and CEO of JAX. "CRISPR technology has transformed genetic engineering in nearly all biological systems. This license allows us to deliver custom-built mouse models, creating the next generation of predictive models for the new era of personalized medicine."